Conv. Plasma
Nigella Sativa

All colchicine studies
Meta analysis
study COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 43% Improvement Relative Risk Ventilation 33% Colchicine for COVID-19  Lien et al.  META ANALYSIS Favors colchicine Favors control

Repurposing Colchicine in Treating Patients with COVID-19: A Systematic Review and Meta-Analysis

Lien et al., Life, doi:10.3390/life11080864
Aug 2021  
  Source   PDF   All   Meta
Colchicine for COVID-19
5th treatment shown to reduce risk in September 2020
*, now known with p = 0.00000018 from 53 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments.
Meta analysis of 11 colchicine studies showing significantly lower mortality with treatment.
10 meta analyses show significant improvements with colchicine for mortality Danjuma, Elshafei, Elshiwy, Golpour, Lien, Rai, Salah, Zein, oxygen therapy Elshiwy, hospitalization Kow, and severity Yasmin.
Currently there are 53 colchicine for COVID-19 studies, showing 29% lower mortality [19‑39%], 29% lower ventilation [-15‑56%], 31% lower ICU admission [4‑51%], 19% lower hospitalization [10‑27%], and 9% more cases [-8‑29%].
risk of death, 43.0% lower, OR 0.57, p = 0.008, RR approximated with OR.
risk of mechanical ventilation, 33.0% lower, OR 0.67, p = 0.15, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Lien et al., 23 Aug 2021, peer-reviewed, 12 authors. Contact: (corresponding author),,,,,,,,,,,
This PaperColchicineAll
Repurposing Colchicine in Treating Patients with COVID-19: A Systematic Review and Meta-Analysis
Chi-Hone Lien, Ming-Dar Lee, Shun-Long Weng, Chao-Hsu Lin, Lawrence Yu-Min Liu, Yu-Lin Tai, Wei-Te Lei, Jui-Ming Liu, Ya-Ning Huang, Hsin Chi, Nan-Chang Chiu, Chien-Yu Lin
Life, doi:10.3390/life11080864
Coronavirus disease 2019 (COVID-19) had caused huge health losses worldwide. Several drugs had been applied to treat patients with COVID-19, and repurposing colchicine had been proposed for its anti-inflammatory properties via several pathways. In this systematic review, we evaluated the effects of colchicine treatment. From inception to May 31, 2021, databases, including PubMed, EMbase, medRxiv, and Research Square were searched, and 11 studies were enrolled. A total of 17,205 COVID-19 patients with male predominance (62.9%) were analyzed. Patients with colchicine treatment had a significantly lower risk of mortality (odds ratio (OR): 0.57, 95% confidence interval (CI): 0.38-0.87, I 2 : 72%; p < 0.01) and a non-significantly lower rate of mechanical ventilation (OR: 0.67, 95%CI: 0.39-1.15). The side effects were mild and not significantly different (OR: 2.03, 95%CI: 0.51-8.09). Subgroup analysis with randomized controlled trials showed no statistically significant difference in the mortality (OR: 0.80, 95%CI: 0.44-1.46, I 2 : 33%; p = 0.22). In conclusion, our meta-analysis found that colchicine treatment was associated with a significantly lower risk of mortality in patients with COVID-19. However, this benefit was not observed in the subgroup analysis of randomized controlled trials. Further randomized controlled studies are required to confirm the potential benefits of colchicine treatment.
Conclusions In conclusion, our systematic review and meta-analysis identified 17,205 COVID-19 patients, and we found that a significant reduction in mortality in patients with colchicine treatment (OR: 0.57). The results were similar with subgroup analysis for different mortality rates. However, moderate heterogeneity was observed, and the dose, interval, duration, and mortality rate varied across studies. Further subgroup analysis with randomized controlled trials showed a non-significant decrease. Funnel plots and Egger's test demonstrated a significant publication bias in both meta-analysis of all studies and randomized controlled trials. Therefore, further well-designed randomized controlled trials were required to elucidate the benefits of colchicine treatment and determine the optimal regimen. Although colchicine was cheap, easily available, accessible, and safe, routine colchicine treatment was not recommended based on our systematic review and meta-analysis. Supplementary Materials: The following are available online at .3390/life11080864/s1, Supplementary File S1, Complete search strategy of our systematic review. Supplementary File S2, Funnel plot of enrolled studies investigating the subsequent mortality of colchicine and control groups. Supplementary File S3, Contour-enhanced funnel plot of enrolled studies investigating subsequent mortality of colchicine and control groups. Supplementary File S4, Egger's test of enrolled studies..
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the treatment of COVID-19-Final report, N. Engl. J. Med, doi:10.1056/NEJMoa2007764
Brunetti, Diawara, Tsai, Firestein, Nahass et al., Colchicine to weather the cytokine storm in hospitalized patients with COVID-19, J. Clin. Med, doi:10.3390/jcm9092961
Chen, Tseng, Choi, Lee, Su et al., Taiwan government-guided strategies contributed to combating and controlling COVID-19 pandemic, Front. Public Health
Chi, Chiu, Peng, Lin, Tai et al., One-seventh of patients with COVID-19 had olfactory and gustatory abnormalities as their initial symptoms: A systematic review and meta-analysis, Life, doi:10.3390/life10090158
Chi, Chiu, Tai, Chang, Lin et al., Clinical features of neonates born to mothers with coronavirus disease-2019: A ssytematic review of 105 neonates, J. Microbiol. Immunol. Infect
Dalbeth, Lauterio, Wolfe, Mechanism of action of colchicine in the treatment of gout, Clin. Ther
De Rivero Vaccari, Dietrich, Keane, De Rivero, Vaccari, The inflammasome in times of COVID-19, Front. Immunol, doi:10.3389/fimmu.2020.583373
Deftereos, Giannopoulos, Vrachatis, Siasos, Giotaki et al., Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: The grecco-19 randomized clinical trial, JAMA Netw. Open, doi:10.1001/jamanetworkopen.2020.13136
Dupuis, Sirois, Rhéaume, Nguyen, Clavet-Lanthier et al., Colchicine reduces lung injury in experimental acute respiratory distress syndrome, PLoS ONE, doi:10.1371/journal.pone.0242318
Egger, Smith, Schneider, Minder, Bias in meta-analysis detected by a simple, graphical test, BMJ, doi:10.1136/bmj.315.7109.629
Fajgenbaum, June, Cytokine storm, N. Engl. J. Med, doi:10.1056/NEJMra2026131
Freeman, Swartz, Targeting the nlrp3 inflammasome in severe COVID-19, Front. Immunol, doi:10.3389/fimmu.2020.01518
García-Posada, Aruachan-Vesga, Mestra, Humánez, Serrano-Coll et al., Clinical outcomes of patients hospitalized for COVID-19 and evidence-based on the pharmacological management reduce mortality in a region of the colombian caribbean, J. Infect. Public Health, doi:10.1016/j.jiph.2021.02.013
Hariyanto, Halim, Jodhinata, Yanto, Kurniawan, Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis, Clin. Exp. Pharm. Physiol, doi:10.1111/1440-1681.13488
Higgins, Thomas, Chandler, Cumpston, Li et al., Cochrane Handbook for Systematic Reviews Ofinterventions Version
Higgins, Thompson, Deeks, Altman, Measuring inconsistency in meta-analyses, BMJ
Horby, Campbell, Spata, Emberson, Staplin et al., COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial, doi:10.1101/2021.05.18.21257267
Kevorkian, Lopes, Sène, Riveline, Vandiedonck et al., Oral corticoid, aspirin, anticoagulant, colchicine, and furosemide to improve the outcome of hospitalized COVID-19 patients-The cocaa-cola cohort study, J. Infect, doi:10.1016/j.jinf.2021.02.008
Kowalewski, Fina, Słomka, Raffa, Martucci et al., Covid-19 and ecmo: The interplay between coagulation and inflammation-A narrative review, Crit. Care
Leung, Yao Hui, Kraus, Colchicine-Update on mechanisms of action and therapeutic uses, Semin. Arthritis Rheum, doi:10.1016/j.semarthrit.2015.06.013
Lopes, Bonjorno, Giannini, Amaral, Menezes et al., Beneficial effects of colchicine for moderate to severe COVID-19: A randomised, double-blinded, placebo-controlled clinical trial, RMD Open, doi:10.1136/rmdopen-2020-001455
Mahale, Rajhans, Godavarthy, Narasimhan, Oak et al., A retrospective observational study of hypoxic COVID-19 patients treated with immunomodulatory drugs in a tertiary care hospital, Indian J. Crit. Care Med
Martínez, Celermajer, Patel, The nlrp3 inflammasome and the emerging role of colchicine to inhibit atherosclerosisassociated inflammation, Atherosclerosis, doi:10.1016/j.atherosclerosis.2017.12.027
Martínez, Robertson, Barraclough, Xia, Mallat et al., Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome, J. Am. Heart Assoc, doi:10.1161/JAHA.115.002128
Page, Mckenzie, Bossuyt, Boutron, Hoffmann et al., The prisma 2020 statement: An updated guideline for reporting systematic reviews, BMJ
Pinzón, Arango, Betancur, Holguín, Arias et al., Clinical outcome of patients with COVID-19 pneumonia treated with corticosteroids and colchicine in colombia, ResearchSquare
Rabaan, Al-Ahmed, Garout, Al-Qaaneh, Sule et al., Diverse immunological factors influencing pathogenesis in patients with COVID-19: A review on viral dissemination, immunotherapeutic options to counter cytokine storm and inflammatory responses, Pathogens, doi:10.3390/pathogens10050565
Sandhu, Tieng, Chilimuri, Franchin, A case control study to evaluate the impact of colchicine on patients admitted to the hospital with moderate to severe COVID-19 infection, Can. J. Infect. Dis. Med. Microbiol, doi:10.1155/2020/8865954
Scarsi, Piantoni, Colombo, Airó, Richini et al., Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome, Ann. Rheum. Dis, doi:10.1136/annrheumdis-2020-217712
Schlesinger, Firestein, Brunetti, Colchicine in COVID-19: An old drug, new use, Curr. Pharmacol. Rep, doi:10.1007/s40495-020-00225-6
Shah, Novel coronavirus-induced nlrp3 inflammasome activation: A potential drug target in the treatment of COVID-19, Front. Immunol, doi:10.3389/fimmu.2020.01021
Siemieniuk, Bartoszko, Ge, Zeraatkar, Izcovich et al., Drug treatments for COVID-19: Living systematic review and network meta-analysis, BMJ
Sterne, Murthy, Diaz, Slutsky, Villar et al., Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis, JAMA
Stewart, Yang, Atkins, Dalbeth, Robinson, Adverse events during oral colchicine use: A systematic review and meta-analysis of randomised controlled trials, Arthritis Res. Ther, doi:10.1186/s13075-020-2120-7
Swanson, Deng, Ting, The nlrp3 inflammasome: Molecular activation and regulation to therapeutics, Nat. Rev. Immunol, doi:10.1038/s41577-019-0165-0
Tardif, Bouabdallaoui, L'allier, Gaudet, Shah et al., Colchicine for community-treated patients with COVID-19 (COLCORONA): A phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial, Lancet Respir. Med, doi:10.1016/S2213-2600(21)00222-8
Van Den Berg, Velde, Severe COVID-19: Nlrp3 inflammasome dysregulated, Front. Immunol, doi:10.3389/fimmu.2020.01580
Wells, Shea, O'connell, The Newcastle-Ottawa Scale (nos) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses
Yuki, Fujiogi, Koutsogiannaki, COVID-19 pathophysiology: A review, Clin. Immunol, doi:10.1016/j.clim.2020.108427
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop